Company Overview

A targeted approach to activate cellular clearance

Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle.  Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).

Urgent and increasing medical need

More than 25 million Americans currently suffer from neurodegenerative or rare diseases with great unmet need as there are few, if any, treatments.  Caraway is developing therapeutics with the potential to alter the progression of the disease and help patients maintain neuronal health and function.

Caraway is positioned to make a difference

The Caraway team includes world-class scientists experienced in drug discovery for novel disease targets. Caraway’s programs take advantage of the endogenous cellular cleaning mechanisms. Because accumulations of toxic materials occur in many diseases including neurodegenerative and lysosomal storage diseases, the Caraway approach has broad therapeutic potential. The company is backed by investors with world-class expertise in central nervous system diseases.